PMID- 33645019
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 46
IP  - 3
DP  - 2021 Feb
TI  - [Research progress and analysis on mechanism of polysaccharides against type 2 
      diabetes mellitus].
PG  - 552-559
LID - 10.19540/j.cnki.cjcmm.20201125.601 [doi]
AB  - Polysaccharides are macromolecular compounds formed by more than 10 
      monosaccharide molecules linked by glycosidic bonds. Polysaccharides have a wide 
      range of sources, high safety and low toxicity, with a variety of biological 
      activities, such as anti-tumor, anti-virus, immune regulation, lowering blood 
      glucose, and lowering blood lipids. Type 2 diabetes mellitus(T2 DM) is a chronic 
      metabolic disorder characterized by hyperglycemia, insulin resistance and low 
      inflammation. In recent years, the treatment of T2 DM with polysaccharide has 
      become a research hotspot. Polysaccharides can not only make up for the side 
      effects such as hypoglycemia, weight gain, gastrointestinal injury caused by 
      long-term treatment of acarbose, biguanidine and sulfonylurea, but also play an 
      effective role in reducing glucose by regulating glucose metabolism, oxidative 
      stress, inflammatory response, intestinal flora, etc. In this paper, the research 
      progress of polysaccharides in the treatment of T2 DM was reviewed. In addition, 
      the hot spots such as the hypoglycemic activity of polysaccharides with 
      structural modifications were summarized, providing theoretical guidance for the 
      development of active polysaccharide hypoglycemic medicines and the further study 
      of action mechanism.
FAU - Liu, Fu-Jun
AU  - Liu FJ
AD  - Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College 
      of Life Science and Technology,Xinjiang University Urumqi 830046, China.
FAU - Liu, Xiao-Ying
AU  - Liu XY
AD  - Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College 
      of Life Science and Technology,Xinjiang University Urumqi 830046, China.
FAU - Ma, Yu
AU  - Ma Y
AD  - Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College 
      of Life Science and Technology,Xinjiang University Urumqi 830046, China.
FAU - Wang, Wei-Lan
AU  - Wang WL
AD  - Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College 
      of Life Science and Technology,Xinjiang University Urumqi 830046, China.
FAU - Li, Jin-Yao
AU  - Li JY
AD  - Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College 
      of Life Science and Technology,Xinjiang University Urumqi 830046, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Polysaccharides)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology
MH  - *Insulin Resistance
MH  - Polysaccharides
OTO - NOTNLM
OT  - gut microbiota
OT  - intracellular signaling pathway
OT  - polysaccharides
OT  - polysaccharides modification
OT  - type 2 diabetes mellitus
EDAT- 2021/03/02 06:00
MHDA- 2021/03/03 06:00
CRDT- 2021/03/01 05:46
PHST- 2021/03/01 05:46 [entrez]
PHST- 2021/03/02 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20201125.601 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2021 Feb;46(3):552-559. doi: 
      10.19540/j.cnki.cjcmm.20201125.601.